LUCENTIS Israel - English - Ministry of Health

lucentis

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)

MERIDIAN TURF INSECTICIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

meridian turf insecticide

syngenta australia pty ltd - thiamethoxam - water dispersible granule - thiamethoxam thiazole active 250.0 g/kg - insecticide - turf and lawn - african black beetle - 1st instar larvae | argentinian scarab - first instar larvae | bill bug - larvae | billbug | la plata weevil

MORPHINE SULFATE injection United States - English - NLM (National Library of Medicine)

morphine sulfate injection

meridian medical technologies, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg in 0.7 ml - morphine sulfate injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve morphine sulfate injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia morphine sulfate injection is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - concurrent use of monoamine oxidase inhibitors (maois) or use of maois within the last 14 days [see warnings and pr

Eylea European Union - English - EMA (European Medicines Agency)

eylea

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

LUCENTIS ranibizumab (rbe) 1.65 mg/0.165 mL solution for injection prefilled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

lucentis ranibizumab (rbe) 1.65 mg/0.165 ml solution for injection prefilled syringe

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

LUCENTIS ranibizumab (rbe) 2.3 mg/0.23 mL (10mg/mL) solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

lucentis ranibizumab (rbe) 2.3 mg/0.23 ml (10mg/ml) solution for injection vial

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd), ? the treatment of visual impairment due to diabetic macular oedema (dme), ? treatment of proliferative diabetic retinopathy (pdr), ? the treatment of visual impairment due to choroidal neovascularisation, ? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), ? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,lucentis is indicated in preterm infants for:,? the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.

EYLEA Israel - English - Ministry of Health

eylea

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Beijing Jiashi Zhengtong Technologies Meridian Ebb-flow Therapeutic Device Singapore - English - HSA (Health Sciences Authority)

beijing jiashi zhengtong technologies meridian ebb-flow therapeutic device

meridian impetus holdings pte. ltd. - physical medicine - the device is indicated for knee osteoarthritis. the pain of mild and moderate knee osteoarthritis can be alleviated and improved to some degree.

Meridian Bioscience ImmunoCard STAT! EHEC Singapore - English - HSA (Health Sciences Authority)

meridian bioscience immunocard stat! ehec

all eights (singapore) private limited - microbiology - immunocard stat! ehec is an immunochromatographic rapid test for the qualitative detection of shiga toxins 1 and 2 (also called verotoxins) produced by e.coli in cultures derived from clinical stool specimens. immunocard stat! ehec is used in conjunction with the patient’s clinical symptoms and other laboratory tests to aid in the diagnosis of diseases caused by enterohemorrhagic e. coli (ehec) infections.

MERIDIAN ENDOPROBE laser fiber Singapore - English - HSA (Health Sciences Authority)

meridian endoprobe laser fiber

mandarin opto-medic co pte ltd - ophthalmology - the endoprobes direct the laser energy from the laser unit to which they are connected, by means of total reflection to the desired treatment site. they are designed for intraocular, transscleral and panretinal treatment for the indication of the ophthalmologist to use.